11:50 AM
 | 
Jul 11, 2018
 |  BC Extra  |  Company News

Otsuka acquiring antibody play Visterra

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) is acquiring antibody developer Visterra Inc. (Waltham, Mass.) for $430 million in cash, the companies said Wednesday.

The deal gives Otsuka a pipeline based on Visterra's Hierotope platform, which is designed to target specific, highly networked epitopes believed to be important in the function of antigens. Otsuka said it is prioritizing platform-based R&D, including antibody development platforms, to make...

Read the full 309 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >